Kevin Deane, MD
Enriched profileProfessor of Medicine, Division of Rheumatology (William P. Arend Endowed Chair in Rheumatology Research) · University of Colorado Anschutz Medical Campus
Kevin Deane is Professor of Medicine, Division of Rheumatology (William P. Arend Endowed Chair in Rheumatology Research) at University of Colorado Anschutz Medical Campus. OpenAlex indexes 253 publications with 14,834 citations (h-index 61); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Kevin D. Deane, MD, is Professor of Medicine, Division of Rheumatology (William P. Arend Endowed Chair in Rheumatology Research) at University of Colorado Anschutz Medical Campus, School of Medicine, Division of Rheumatology. The public record shows 253 publications with 14,834 citations (h-index 61), centered on Rheumatoid Arthritis. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 5 companies, 4 NIH-funded awards (2004–2026).
- Most recent indexed publication: 2026 · Arthritis & rheumatology (Hoboken, N.J.)
- Top research focus: Rheumatoid Arthritis
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 40 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Sponsor: University of Colorado, Denver
- Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20252 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Janssen Biotech, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
62.1%TNF inhibitor30.4%Enbrel Sureclick37%Humira(Cf) Pen37%Humira27%Part D<11 patientsFolate Analog Metabolic Inhibitor21.1%Methotrexate100%Part D≥13 patientsAntiparasitic
19.3%Antimalarial19.3%Hydroxychloroquine Sulfate100%Part D<11 patientsMetabolism & gastrointestinal
18.6%Corticosteroid18.6%Prednisone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2004–2026 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Increased plasma microbial tDR-1 in at-risk individuals is associated with decreased conversion to clinical rheumatoid arthritis and reduces an in vitro macrophage type 1 interferon response.
Arthritis & rheumatology (Hoboken, N.J.)
Article2026 - A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.
Arthritis & rheumatology (Hoboken, N.J.)
Clinical Trial2026 - EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia.
Arthritis & rheumatology (Hoboken, N.J.)
Article2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Kevin-Deane-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
rheumnow.live/b/sp/kevin-deane-1263
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumnow.live ↗ - Other
healio.com/news/rheumatology/20250124/hooked-on-rheum-with-kevin-d-deane-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Editorial & leadership roles
journal and society appointments- Principal Investigator
StopRA (NIH/NIAID-sponsored trial evaluating hydroxychloroquine to prevent/delay rheumatoid arthritis in high-risk individuals)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchealth.org ↗ - Member
American College of Rheumatology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →som.cuanschutz.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →som.cuanschutz.edu ↗
Secondary affiliations
appointments beyond the home institution- Population and Data Sciences Core Service Center (PDSC)
Division of Rheumatology, CU Anschutz
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medschool.cuanschutz.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
- Author
"Rheumatoid arthritis has no cure – but researchers are homing in on preventing it," The Conversation (republished by CU Anschutz News, Yahoo Health, Study Finds, Japan Today)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →theconversation.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Schulick, MD, MBA
University of Colorado Anschutz Medical Campus
John Rumsfeld, MD, PhD
University of Colorado Anschutz Medical Campus
Robert Eckel, MD
University of Colorado Anschutz Medical Campus
Marc Bonaca, MD
University of Colorado Anschutz Medical Campus